Toxicokinetics of the flame retardant hexabromocyclododecane alpha: effect of dose, timing, route, repeated exposure, and metabolism

Alpha-hexabromocyclododecane (α-HBCD) is an emerging persistent organic pollutant present in the hexabromocyclododecane (HBCD) commercial mixture. HBCD is used as an additive flame retardant in a wide variety of household consumer products. Three main stereoisomers, alpha (α), beta (β), and gamma (γ...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Toxicological sciences 2011-06, Vol.121 (2), p.234-244
Hauptverfasser: Szabo, David Taylor, Diliberto, Janet J, Hakk, Heldur, Huwe, Janice K, Birnbaum, Linda S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 244
container_issue 2
container_start_page 234
container_title Toxicological sciences
container_volume 121
creator Szabo, David Taylor
Diliberto, Janet J
Hakk, Heldur
Huwe, Janice K
Birnbaum, Linda S
description Alpha-hexabromocyclododecane (α-HBCD) is an emerging persistent organic pollutant present in the hexabromocyclododecane (HBCD) commercial mixture. HBCD is used as an additive flame retardant in a wide variety of household consumer products. Three main stereoisomers, alpha (α), beta (β), and gamma (γ), comprise roughly 10, 10, and 80% of the mixture, respectively. Despite its small contribution to HBCD global production and usage, α-HBCD is the major stereoisomer found in wildlife and human tissues including breast milk and blood in North America, European Union, and Asia. No mammalian or human data are currently available regarding the toxicokinetics of α-HBCD. This study was conducted in an effort to fully characterize the absorption, distribution, metabolism, and elimination of α-HBCD following a single and repeated exposure with respect to dose, time, and route of administration in female C57BL/6 mice. Results indicate that ∼90% of the administered dose (3 mg/kg) was absorbed after oral exposure. Disposition was (1) dictated by lipophilicity, as adipose, liver, muscle, and skin were major depots and (2) was dose dependent with nonlinear accumulation at higher doses. Elimination, both whole-body and from individual tissues, was biphasic. α-HBCD-derived radioactivity was excreted in the feces as parent and metabolites, whereas urine only contained metabolites. Presence of polar metabolites in the blood and urine were a major factor in determining the rapid initial whole-body half-life after a single oral exposure. Initial half-lives were ∼1-3 days and much longer terminal half-lives of 17 days were observed, suggesting the potential for α-HBCD bioaccumulation. A 10-day repeated study supports α-HBCD bioaccumulation potential. Stereoisomerization previously observed after exposure to γ-HBCD was not seen after exposure of α-HBCD. The toxicokinetic behavior reported here has important implications for the extrapolation of toxicological studies of the commercial HBCD mixture to the assessment of risk of α-HBCD which is the major stereoisomer found in wildlife and people.
doi_str_mv 10.1093/toxsci/kfr059
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_toxsci_kfr059</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21441408</sourcerecordid><originalsourceid>FETCH-LOGICAL-c331t-2a2bab04dd6c9c282820b362a61c4a5dedd9ba16e39b555365138fce7f2a7cc83</originalsourceid><addsrcrecordid>eNo9kM1OwzAQhC0EolA4ckV-gIbacZLG3FDFn1SJSzlHa3tNQ5M4sl0pvfPgpGpBe9id0ewcPkLuOHvgTIp5dEPQ9XxrPcvlGbkazSJhMpXnp7tgJZuQ6xC-GeO8YPKSTFKeZTxj5RX5Wbuh1m5bdxhrHaizNG6Q2gZapB4jeANdpBscQHnXOr3XjTPOoIYOKTT9Bh4pWos6Hn6NCzijsW7r7mtGvdvFUXrsESIaikPvws6PFnSGtmO7ck0d2htyYaEJeHvaU_L58rxeviWrj9f35dMq0ULwmKSQKlAsM6bQUqflOEyJIoWC6wxyg8ZIBbxAIVWe56LIuSitxoVNYaF1KaYkOfZq70LwaKve1y34fcVZdaBZHWlWR5pj_v6Y73eqRfOf_sMnfgExpHY4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Toxicokinetics of the flame retardant hexabromocyclododecane alpha: effect of dose, timing, route, repeated exposure, and metabolism</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Szabo, David Taylor ; Diliberto, Janet J ; Hakk, Heldur ; Huwe, Janice K ; Birnbaum, Linda S</creator><creatorcontrib>Szabo, David Taylor ; Diliberto, Janet J ; Hakk, Heldur ; Huwe, Janice K ; Birnbaum, Linda S</creatorcontrib><description>Alpha-hexabromocyclododecane (α-HBCD) is an emerging persistent organic pollutant present in the hexabromocyclododecane (HBCD) commercial mixture. HBCD is used as an additive flame retardant in a wide variety of household consumer products. Three main stereoisomers, alpha (α), beta (β), and gamma (γ), comprise roughly 10, 10, and 80% of the mixture, respectively. Despite its small contribution to HBCD global production and usage, α-HBCD is the major stereoisomer found in wildlife and human tissues including breast milk and blood in North America, European Union, and Asia. No mammalian or human data are currently available regarding the toxicokinetics of α-HBCD. This study was conducted in an effort to fully characterize the absorption, distribution, metabolism, and elimination of α-HBCD following a single and repeated exposure with respect to dose, time, and route of administration in female C57BL/6 mice. Results indicate that ∼90% of the administered dose (3 mg/kg) was absorbed after oral exposure. Disposition was (1) dictated by lipophilicity, as adipose, liver, muscle, and skin were major depots and (2) was dose dependent with nonlinear accumulation at higher doses. Elimination, both whole-body and from individual tissues, was biphasic. α-HBCD-derived radioactivity was excreted in the feces as parent and metabolites, whereas urine only contained metabolites. Presence of polar metabolites in the blood and urine were a major factor in determining the rapid initial whole-body half-life after a single oral exposure. Initial half-lives were ∼1-3 days and much longer terminal half-lives of 17 days were observed, suggesting the potential for α-HBCD bioaccumulation. A 10-day repeated study supports α-HBCD bioaccumulation potential. Stereoisomerization previously observed after exposure to γ-HBCD was not seen after exposure of α-HBCD. The toxicokinetic behavior reported here has important implications for the extrapolation of toxicological studies of the commercial HBCD mixture to the assessment of risk of α-HBCD which is the major stereoisomer found in wildlife and people.</description><identifier>ISSN: 1096-6080</identifier><identifier>EISSN: 1096-0929</identifier><identifier>DOI: 10.1093/toxsci/kfr059</identifier><identifier>PMID: 21441408</identifier><language>eng</language><publisher>United States</publisher><subject>Administration, Oral ; Animals ; Biotransformation ; Chromatography, Liquid ; Chromatography, Thin Layer ; Dose-Response Relationship, Drug ; Endocrine Disruptors - pharmacokinetics ; Female ; Flame Retardants - pharmacokinetics ; Hydrocarbons, Brominated - pharmacokinetics ; Injections, Intravenous ; Mass Spectrometry ; Mice ; Mice, Inbred C57BL ; Nonlinear Dynamics ; Risk Assessment ; Time Factors ; Tissue Distribution</subject><ispartof>Toxicological sciences, 2011-06, Vol.121 (2), p.234-244</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c331t-2a2bab04dd6c9c282820b362a61c4a5dedd9ba16e39b555365138fce7f2a7cc83</citedby><cites>FETCH-LOGICAL-c331t-2a2bab04dd6c9c282820b362a61c4a5dedd9ba16e39b555365138fce7f2a7cc83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21441408$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Szabo, David Taylor</creatorcontrib><creatorcontrib>Diliberto, Janet J</creatorcontrib><creatorcontrib>Hakk, Heldur</creatorcontrib><creatorcontrib>Huwe, Janice K</creatorcontrib><creatorcontrib>Birnbaum, Linda S</creatorcontrib><title>Toxicokinetics of the flame retardant hexabromocyclododecane alpha: effect of dose, timing, route, repeated exposure, and metabolism</title><title>Toxicological sciences</title><addtitle>Toxicol Sci</addtitle><description>Alpha-hexabromocyclododecane (α-HBCD) is an emerging persistent organic pollutant present in the hexabromocyclododecane (HBCD) commercial mixture. HBCD is used as an additive flame retardant in a wide variety of household consumer products. Three main stereoisomers, alpha (α), beta (β), and gamma (γ), comprise roughly 10, 10, and 80% of the mixture, respectively. Despite its small contribution to HBCD global production and usage, α-HBCD is the major stereoisomer found in wildlife and human tissues including breast milk and blood in North America, European Union, and Asia. No mammalian or human data are currently available regarding the toxicokinetics of α-HBCD. This study was conducted in an effort to fully characterize the absorption, distribution, metabolism, and elimination of α-HBCD following a single and repeated exposure with respect to dose, time, and route of administration in female C57BL/6 mice. Results indicate that ∼90% of the administered dose (3 mg/kg) was absorbed after oral exposure. Disposition was (1) dictated by lipophilicity, as adipose, liver, muscle, and skin were major depots and (2) was dose dependent with nonlinear accumulation at higher doses. Elimination, both whole-body and from individual tissues, was biphasic. α-HBCD-derived radioactivity was excreted in the feces as parent and metabolites, whereas urine only contained metabolites. Presence of polar metabolites in the blood and urine were a major factor in determining the rapid initial whole-body half-life after a single oral exposure. Initial half-lives were ∼1-3 days and much longer terminal half-lives of 17 days were observed, suggesting the potential for α-HBCD bioaccumulation. A 10-day repeated study supports α-HBCD bioaccumulation potential. Stereoisomerization previously observed after exposure to γ-HBCD was not seen after exposure of α-HBCD. The toxicokinetic behavior reported here has important implications for the extrapolation of toxicological studies of the commercial HBCD mixture to the assessment of risk of α-HBCD which is the major stereoisomer found in wildlife and people.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Biotransformation</subject><subject>Chromatography, Liquid</subject><subject>Chromatography, Thin Layer</subject><subject>Dose-Response Relationship, Drug</subject><subject>Endocrine Disruptors - pharmacokinetics</subject><subject>Female</subject><subject>Flame Retardants - pharmacokinetics</subject><subject>Hydrocarbons, Brominated - pharmacokinetics</subject><subject>Injections, Intravenous</subject><subject>Mass Spectrometry</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Nonlinear Dynamics</subject><subject>Risk Assessment</subject><subject>Time Factors</subject><subject>Tissue Distribution</subject><issn>1096-6080</issn><issn>1096-0929</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kM1OwzAQhC0EolA4ckV-gIbacZLG3FDFn1SJSzlHa3tNQ5M4sl0pvfPgpGpBe9id0ewcPkLuOHvgTIp5dEPQ9XxrPcvlGbkazSJhMpXnp7tgJZuQ6xC-GeO8YPKSTFKeZTxj5RX5Wbuh1m5bdxhrHaizNG6Q2gZapB4jeANdpBscQHnXOr3XjTPOoIYOKTT9Bh4pWos6Hn6NCzijsW7r7mtGvdvFUXrsESIaikPvws6PFnSGtmO7ck0d2htyYaEJeHvaU_L58rxeviWrj9f35dMq0ULwmKSQKlAsM6bQUqflOEyJIoWC6wxyg8ZIBbxAIVWe56LIuSitxoVNYaF1KaYkOfZq70LwaKve1y34fcVZdaBZHWlWR5pj_v6Y73eqRfOf_sMnfgExpHY4</recordid><startdate>201106</startdate><enddate>201106</enddate><creator>Szabo, David Taylor</creator><creator>Diliberto, Janet J</creator><creator>Hakk, Heldur</creator><creator>Huwe, Janice K</creator><creator>Birnbaum, Linda S</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201106</creationdate><title>Toxicokinetics of the flame retardant hexabromocyclododecane alpha: effect of dose, timing, route, repeated exposure, and metabolism</title><author>Szabo, David Taylor ; Diliberto, Janet J ; Hakk, Heldur ; Huwe, Janice K ; Birnbaum, Linda S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c331t-2a2bab04dd6c9c282820b362a61c4a5dedd9ba16e39b555365138fce7f2a7cc83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Biotransformation</topic><topic>Chromatography, Liquid</topic><topic>Chromatography, Thin Layer</topic><topic>Dose-Response Relationship, Drug</topic><topic>Endocrine Disruptors - pharmacokinetics</topic><topic>Female</topic><topic>Flame Retardants - pharmacokinetics</topic><topic>Hydrocarbons, Brominated - pharmacokinetics</topic><topic>Injections, Intravenous</topic><topic>Mass Spectrometry</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Nonlinear Dynamics</topic><topic>Risk Assessment</topic><topic>Time Factors</topic><topic>Tissue Distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Szabo, David Taylor</creatorcontrib><creatorcontrib>Diliberto, Janet J</creatorcontrib><creatorcontrib>Hakk, Heldur</creatorcontrib><creatorcontrib>Huwe, Janice K</creatorcontrib><creatorcontrib>Birnbaum, Linda S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Toxicological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Szabo, David Taylor</au><au>Diliberto, Janet J</au><au>Hakk, Heldur</au><au>Huwe, Janice K</au><au>Birnbaum, Linda S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Toxicokinetics of the flame retardant hexabromocyclododecane alpha: effect of dose, timing, route, repeated exposure, and metabolism</atitle><jtitle>Toxicological sciences</jtitle><addtitle>Toxicol Sci</addtitle><date>2011-06</date><risdate>2011</risdate><volume>121</volume><issue>2</issue><spage>234</spage><epage>244</epage><pages>234-244</pages><issn>1096-6080</issn><eissn>1096-0929</eissn><abstract>Alpha-hexabromocyclododecane (α-HBCD) is an emerging persistent organic pollutant present in the hexabromocyclododecane (HBCD) commercial mixture. HBCD is used as an additive flame retardant in a wide variety of household consumer products. Three main stereoisomers, alpha (α), beta (β), and gamma (γ), comprise roughly 10, 10, and 80% of the mixture, respectively. Despite its small contribution to HBCD global production and usage, α-HBCD is the major stereoisomer found in wildlife and human tissues including breast milk and blood in North America, European Union, and Asia. No mammalian or human data are currently available regarding the toxicokinetics of α-HBCD. This study was conducted in an effort to fully characterize the absorption, distribution, metabolism, and elimination of α-HBCD following a single and repeated exposure with respect to dose, time, and route of administration in female C57BL/6 mice. Results indicate that ∼90% of the administered dose (3 mg/kg) was absorbed after oral exposure. Disposition was (1) dictated by lipophilicity, as adipose, liver, muscle, and skin were major depots and (2) was dose dependent with nonlinear accumulation at higher doses. Elimination, both whole-body and from individual tissues, was biphasic. α-HBCD-derived radioactivity was excreted in the feces as parent and metabolites, whereas urine only contained metabolites. Presence of polar metabolites in the blood and urine were a major factor in determining the rapid initial whole-body half-life after a single oral exposure. Initial half-lives were ∼1-3 days and much longer terminal half-lives of 17 days were observed, suggesting the potential for α-HBCD bioaccumulation. A 10-day repeated study supports α-HBCD bioaccumulation potential. Stereoisomerization previously observed after exposure to γ-HBCD was not seen after exposure of α-HBCD. The toxicokinetic behavior reported here has important implications for the extrapolation of toxicological studies of the commercial HBCD mixture to the assessment of risk of α-HBCD which is the major stereoisomer found in wildlife and people.</abstract><cop>United States</cop><pmid>21441408</pmid><doi>10.1093/toxsci/kfr059</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1096-6080
ispartof Toxicological sciences, 2011-06, Vol.121 (2), p.234-244
issn 1096-6080
1096-0929
language eng
recordid cdi_crossref_primary_10_1093_toxsci_kfr059
source MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection; Free Full-Text Journals in Chemistry
subjects Administration, Oral
Animals
Biotransformation
Chromatography, Liquid
Chromatography, Thin Layer
Dose-Response Relationship, Drug
Endocrine Disruptors - pharmacokinetics
Female
Flame Retardants - pharmacokinetics
Hydrocarbons, Brominated - pharmacokinetics
Injections, Intravenous
Mass Spectrometry
Mice
Mice, Inbred C57BL
Nonlinear Dynamics
Risk Assessment
Time Factors
Tissue Distribution
title Toxicokinetics of the flame retardant hexabromocyclododecane alpha: effect of dose, timing, route, repeated exposure, and metabolism
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T20%3A03%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Toxicokinetics%20of%20the%20flame%20retardant%20hexabromocyclododecane%20alpha:%20effect%20of%20dose,%20timing,%20route,%20repeated%20exposure,%20and%20metabolism&rft.jtitle=Toxicological%20sciences&rft.au=Szabo,%20David%20Taylor&rft.date=2011-06&rft.volume=121&rft.issue=2&rft.spage=234&rft.epage=244&rft.pages=234-244&rft.issn=1096-6080&rft.eissn=1096-0929&rft_id=info:doi/10.1093/toxsci/kfr059&rft_dat=%3Cpubmed_cross%3E21441408%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/21441408&rfr_iscdi=true